West Pharmaceutical Services, Inc.
WST
$303.45
-$8.62-2.76%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.22B | 3.07B | 3.02B | 2.96B | 2.90B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.22B | 3.07B | 3.02B | 2.96B | 2.90B |
| Cost of Revenue | 2.05B | 1.97B | 1.94B | 1.92B | 1.90B |
| Gross Profit | 1.17B | 1.10B | 1.07B | 1.04B | 1.00B |
| SG&A Expenses | 402.60M | 389.70M | 365.50M | 346.30M | 334.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.20M | 1.30M | 900.00K | 1.20M | 900.00K |
| Total Operating Expenses | 2.53B | 2.44B | 2.38B | 2.33B | 2.30B |
| Operating Income | 693.30M | 638.70M | 636.30M | 627.20M | 596.70M |
| Income Before Tax | 684.90M | 615.30M | 616.80M | 611.20M | 582.40M |
| Income Tax Expenses | 142.20M | 121.60M | 125.10M | 123.50M | 115.20M |
| Earnings from Continuing Operations | 542.70 | 493.70 | 491.70 | 487.70 | 467.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 542.70M | 493.70M | 491.70M | 487.70M | 467.20M |
| EBIT | 693.30M | 638.70M | 636.30M | 627.20M | 596.70M |
| EBITDA | 869.90M | 810.10M | 801.40M | 789.50M | 756.50M |
| EPS Basic | 7.52 | 6.83 | 6.79 | 6.72 | 6.42 |
| Normalized Basic EPS | 6.20 | 5.72 | 5.68 | 5.58 | 5.29 |
| EPS Diluted | 7.48 | 6.79 | 6.75 | 6.68 | 6.37 |
| Normalized Diluted EPS | 6.17 | 5.69 | 5.64 | 5.54 | 5.25 |
| Average Basic Shares Outstanding | 288.70M | 289.20M | 289.60M | 290.20M | 291.00M |
| Average Diluted Shares Outstanding | 290.20M | 290.80M | 291.40M | 292.20M | 293.40M |
| Dividend Per Share | 0.86 | 0.85 | 0.84 | 0.83 | 0.82 |
| Payout Ratio | 11.39% | 12.40% | 12.34% | 12.32% | 12.76% |